NCT00932022

Trospium Chloride XR in Obese Female Patients With Overactive Bladder

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 127 (actual)
• Sponsor: Allergan · Industry
• Sex: Female
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study evaluated the effectiveness of trospium chloride extended release (XR) in obese female patients with overactive bladder (OAB). Patients received either placebo and trospium chloride XR or placebo only. The study assessed the change from baseline in urinary frequency, urgency, and incontinence for trospium chloride XR versus a placebo-pill. The study was 14 weeks in duration.

Conditions

• Obesity
• Overactive Bladder
• Incontinence

Interventions

Type	Name	Description
DRUG	Trospium Chloride, Extended Release (XR)	Trospium chloride extended release 60 mg capsule taken orally once daily for 12 weeks.
OTHER	placebo	Placebo capsule taken orally once daily for either 2 weeks or 14 weeks.

Timeline

• Start date: 2009-07-01
• Primary completion: 2011-12-01
• Completion: 2011-12-01
• First posted: 2009-07-02
• Last updated: 2013-01-21
• Results posted: 2013-01-21

Locations

1 site across 1 country: United States